SCHEMBL2675147

SCHEMBL2675147

Cc1nc(Cl)ccc1OC(C1CCC1)[C@H]1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SSTR4 P31391 1/20 0.41
▸ PDE4B Q07343 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ TRPV3 Q8NET8 1/20 0.38
▸ GPR119 Q8TDV5 4/20 0.38
▸ TP53 P04637 1/20 0.38
▸ NR3C1 P04150 2/20 0.37
▸ USP30 Q70CQ3 5/20 0.37
▸ SUV39H2 Q9H5I1 1/20 0.36
▸ MMP13 P45452 1/20 0.36
▸ PDE4D Q08499 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676756 0.85 SSTR4 (0.39) SSTR4PDE4BALDH1A1TRPV3GPR119
SCHEMBL590425 0.83 SLC6A2 (0.41) SSTR4NPC1ALDH1A1MAPTMAPK1
SCHEMBL586400 0.83 SSTR4 (0.40) SSTR4PDE4BNPC1ALDH1A1MAPT
SCHEMBL10090874 0.83 SLC6A2 (0.41) SSTR4NPC1ALDH1A1MAPTMAPK1
SCHEMBL26180110 0.79 PIK3CD (0.48) SSTR4PDE4BGPR119PDE4D
SCHEMBL2675233 0.76 GPR119 (0.42) GPR119USP30MMP13
SCHEMBL586093 0.71 EPHX1 (0.49) PDE4BNPC1ALDH1A1MAPTMAPK1
SCHEMBL590981 0.71 SLC6A2 (0.55) PDE4BALDH1A1GPR119MMP13PDE4D
SCHEMBL10090887 0.71 SLC6A2 (0.40) SSTR4MAPTL3MBTL1GPR119
SCHEMBL10090902 0.71 SSTR4 (0.37) SSTR4GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173821-B2 Serotonin and norepinephrine reuptake inhibitor ELI LILLY AND COMPANY (US) 2012-05-08 — — US disclosed
US-8173821-B2 Serotonin and norepinephrine reuptake inhibitor ELI LILLY AND COMPANY (US) 2012-05-08 — — US disclosed
US-8173821-B2 Serotonin and norepinephrine reuptake inhibitor ELI LILLY AND COMPANY (US) 2012-05-08 — — US disclosed
WO-2010117979-A2 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR ELI LILLY AND COMPANY (US) 2010-10-14 — — WO disclosed
US-20100261762-A1 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR ELI LILLY AND COMPANY (US) 2010-10-14 — — US disclosed
US-20100261762-A1 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR ELI LILLY AND COMPANY (US) 2010-10-14 — — US disclosed
US-20100261762-A1 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR ELI LILLY AND COMPANY (US) 2010-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261762-A1 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR SLC6A2, SLC6A4, TPH1 SSTR4 339/4885PDE4B 1018/4885NPC1 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback